H.C. Wainwright Reiterates Buy Rating on Context Therapeutics (CNTX)

March 24, 2026 6:39 AM

H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $5.00 price target on Context Therapeutics (NASDAQ: CNTX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found